Raptor Pharmaceutical Corp Company Profile (NASDAQ:RPTP)

About Raptor Pharmaceutical Corp (NASDAQ:RPTP)

Raptor Pharmaceutical Corp logoRaptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RPTP
  • CUSIP: 75382F10
  • Web: www.horizonpharma.com/
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.45
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -43.75%
  • Return on Equity: -77.01%
  • Return on Assets: -15.64%
Debt:
  • Debt-to-Equity Ratio: 1.33%
  • Current Ratio: 3.57%
  • Quick Ratio: 3.30%
Misc:
  • Beta: 1.18
 

Frequently Asked Questions for Raptor Pharmaceutical Corp (NASDAQ:RPTP)

What is Raptor Pharmaceutical Corp's stock symbol?

Raptor Pharmaceutical Corp trades on the NASDAQ under the ticker symbol "RPTP."

How were Raptor Pharmaceutical Corp's earnings last quarter?

Raptor Pharmaceutical Corp (NASDAQ:RPTP) announced its quarterly earnings results on Thursday, August, 4th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The firm earned $32.05 million during the quarter, compared to analysts' expectations of $28.52 million. Raptor Pharmaceutical Corp had a negative net margin of 43.75% and a negative return on equity of 77.01%. The company's revenue for the quarter was up 37.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) earnings per share. View Raptor Pharmaceutical Corp's Earnings History.

Who are some of Raptor Pharmaceutical Corp's key competitors?

How do I buy Raptor Pharmaceutical Corp stock?

Shares of Raptor Pharmaceutical Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Raptor Pharmaceutical Corp's stock price today?

One share of Raptor Pharmaceutical Corp stock can currently be purchased for approximately $9.00.


MarketBeat Community Rating for Raptor Pharmaceutical Corp (NASDAQ RPTP)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about Raptor Pharmaceutical Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Raptor Pharmaceutical Corp (NASDAQ:RPTP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Price Target History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Analysts' Ratings History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/16/2016Cowen and CompanyDowngradeOutperform -> Market Perform$9.00N/AView Rating Details
9/12/2016WedbushReiterated RatingNeutral$9.00 -> $4.00N/AView Rating Details
9/8/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/8/2016Citigroup Inc.DowngradeBuy -> Neutral$6.00 -> $8.00N/AView Rating Details
4/12/2016Leerink SwannReiterated RatingOutperform$11.00N/AView Rating Details
4/11/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
3/20/2016JMP SecuritiesDowngradeHoldN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Earnings by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Earnings History by Quarter for Raptor Pharmaceutical Corp (NASDAQ RPTP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.18)($0.16)$28.52 million$32.05 millionViewListenView Earnings Details
5/5/2016Q116($0.17)($0.17)$27.17 million$27.47 millionViewN/AView Earnings Details
2/25/2016Q415($0.19)($0.17)$26.08 million$24.67 millionViewListenView Earnings Details
11/5/2015Q315($0.18)($0.18)$24.25 million$25.80 millionViewListenView Earnings Details
8/6/2015Q215($0.21)($0.12)$21.40 million$23.30 millionViewN/AView Earnings Details
5/7/2015Q115($0.25)($0.24)$19.10 million$20.50 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.25)$20.12 million$17.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.18)($0.04)$18.90 million$23.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.19)($0.15)$14.58 million$16.31 millionViewN/AView Earnings Details
5/8/2014Q413($0.17)($0.20)$11.81 million$12.10 millionViewN/AView Earnings Details
3/13/2014Q313($0.18)($0.19)$8.99 million$10.25 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.30)($0.30)ViewN/AView Earnings Details
3/14/2013Q1 2013($0.27)($0.37)ViewN/AView Earnings Details
1/9/2013Q1 2013($0.23)($0.26)$0.25 millionViewN/AView Earnings Details
11/14/2012Q412($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 54.88%
Insider Trades by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Institutional Ownership by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Insider Trades by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/9/2015Suzanne Louise BruhnDirectorSell18,258$12.47$227,677.26View SEC Filing  
9/2/2015Raymond AndersonDirectorSell4,916$12.51$61,499.16View SEC Filing  
8/31/2015Raymond AndersonDirectorSell8,084$12.52$101,211.68View SEC Filing  
7/1/2015Llew KeltnerDirectorSell50,000$16.05$802,500.00View SEC Filing  
6/18/2015Thomas E DaleyInsiderSell35,000$15.00$525,000.00View SEC Filing  
6/10/2015Suzanne Louise BruhnDirectorSell30,000$13.45$403,500.00View SEC Filing  
5/4/2015Richard L FranklinDirectorSell10,000$9.61$96,100.00View SEC Filing  
4/2/2015Richard L FranklinDirectorSell10,000$10.37$103,700.00View SEC Filing  
3/23/2015Christopher M StarrDirectorSell20,033$11.62$232,783.46View SEC Filing  
3/2/2015Richard L FranklinDirectorSell10,000$9.18$91,800.00View SEC Filing  
2/24/2015Christopher M StarrDirectorSell30,000$9.52$285,600.00View SEC Filing  
2/2/2015Richard L FranklinDirectorSell7,109$9.20$65,402.80View SEC Filing  
1/22/2015Christopher M StarrDirectorSell30,000$9.45$283,500.00View SEC Filing  
1/15/2015Christopher M StarrDirectorSell30,000$9.73$291,900.00View SEC Filing  
1/12/2015Raymond AndersonDirectorSell10,000$10.58$105,800.00View SEC Filing  
12/22/2014Christopher M StarrCEOSell30,000$9.00$270,000.00View SEC Filing  
12/15/2014Christopher M StarrCEOSell30,000$8.15$244,500.00View SEC Filing  
11/24/2014Christopher M StarrCEOSell30,000$9.97$299,100.00View SEC Filing  
10/22/2014Christopher M StarrCEOSell30,000$10.25$307,500.00View SEC Filing  
9/23/2014Christopher M StarrCEOSell30,000$10.21$306,300.00View SEC Filing  
9/16/2014Christopher M StarrCEOSell32,896$10.60$348,697.60View SEC Filing  
9/10/2014Raymond AndersonDirectorSell10,000$10.81$108,100.00View SEC Filing  
8/25/2014Erich SagerDirectorSell10,000$11.01$110,100.00View SEC Filing  
7/7/2014Llew KeltnerDirectorSell10,000$11.21$112,100.00View SEC Filing  
5/13/2014Georgia ErbezCFOBuy16,100$7.90$127,190.00View SEC Filing  
4/7/2014Vijay SamantDirectorSell5,000$8.59$42,950.00View SEC Filing  
3/17/2014Christopher StarrCEOSell19,316$10.79$208,419.64View SEC Filing  
1/13/2014Timothy WalbertDirectorSell5,520$15.06$83,131.20View SEC Filing  
1/9/2014Thomas DaleyInsiderSell15,000$14.17$212,550.00View SEC Filing  
1/7/2014Llew KeltnerDirectorSell10,000$13.25$132,500.00View SEC Filing  
1/2/2014Richard FranklinDirectorSell10,715$13.12$140,580.80View SEC Filing  
12/9/2013Vijay SamantDirectorSell5,000$13.86$69,300.00View SEC Filing  
11/13/2013Timothy WalbertDirectorSell5,521$12.44$68,681.24View SEC Filing  
11/4/2013Richard FranklinDirectorSell10,715$14.88$159,439.20View SEC Filing  
10/15/2013Christopher M StarrCEOSell25,000$13.77$344,250.00View SEC Filing  
10/14/2013Suzanne Louise BruhnDirectorSell2,760$13.58$37,480.80View SEC Filing  
10/7/2013Vijay SamantDirectorSell5,000$14.76$73,800.00View SEC Filing  
9/16/2013Christopher StarrCEOSell25,000$14.21$355,250.00View SEC Filing  
9/16/2013Erich SagerDirectorSell17,000$14.21$241,570.00View SEC Filing  
9/13/2013Suzanne Louise BruhnDirectorSell2,760$14.07$38,833.20View SEC Filing  
9/9/2013Richard L FranklinDirectorSell10,715$14.24$152,581.60View SEC Filing  
9/9/2013Thomas E DaleyInsiderSell25,000$14.28$357,000.00View SEC Filing  
8/30/2013Georgia ErbezCFOSell7,400$13.42$99,308.00View SEC Filing  
12/28/2012Raymond AndersonDirectorSell2,000$5.50$11,000.00View SEC Filing  
11/26/2012Erich SagerDirectorSell11,279$5.00$56,395.00View SEC Filing  
9/12/2012Raymond AndersonDirectorSell2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Latest Headlines for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Source:

Social

Chart

Raptor Pharmaceutical Corp (RPTP) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.